新型CRISPR基因编辑技术可用于靶向扩增的抗生素抗性基因

2019-12-17 不详 MedSci原创

美国加利福尼亚大学圣地亚哥分校的科学家们开发了新型基于CRISPR的基因驱动系统Pro-AG,该系统显着提高了灭活细菌耐药性基因的效率。该研究于12月16日发表在《Nature communications》杂志上。

美国加利福尼亚大学圣地亚哥分校的科学家们开发了新型基于CRISPR的基因驱动系统Pro-AG,该系统显着提高了灭活细菌耐药性基因的效率。该研究于12月16日发表在《Nature communications》杂志上。

抗生素的广泛使用已导致环境中抗菌素耐药性的上升。健康专家预测,在未来几十年中,抗生素耐药性的威胁可能会急剧增加,如果不加控制,到2050年每年将导致约一千万的耐药性疾病死亡。

Pro-AG是基于CRISPR-Cas9基因编辑技术的改进。Pro-AG系统解决了一个棘手的问题,即以质粒,环状DNA形式存在的抗生素耐药性,这种环状DNA可以独立于细菌基因组复制。携带抗生素抗性基因的质粒的多拷贝或"扩增质粒"可以存在于每个细菌中,并具有在细菌之间转移抗生素抗性的能力,从而对成功治疗提出了艰巨的挑战。Pro-AG通过插入修复机制来破坏抗生素抗性基因的活性,其效率比目前的插入和破坏方法高至少两个数量级。

研究人员实验培养物中证明了新技术的有效性。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1655567, encodeId=176a165556ed0, content=<a href='/topic/show?id=853555428cc' target=_blank style='color:#2F92EE;'>#抗生素抗性基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55428, encryptionId=853555428cc, topicName=抗生素抗性基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4f5024728688, createdName=lily1624, createdTime=Fri Oct 30 14:11:00 CST 2020, time=2020-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744381, encodeId=77c51e4438180, content=<a href='/topic/show?id=42a7523823' target=_blank style='color:#2F92EE;'>#CRISPR基因编辑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5238, encryptionId=42a7523823, topicName=CRISPR基因编辑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e1c35375117, createdName=guguangxiang, createdTime=Sun Jun 07 18:11:00 CST 2020, time=2020-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666011, encodeId=4de216660110e, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Fri Nov 20 08:11:00 CST 2020, time=2020-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276137, encodeId=ee3612e613757, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Thu Dec 19 12:11:00 CST 2019, time=2019-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630173, encodeId=bfcd16301e33d, content=<a href='/topic/show?id=d81a4186e3f' target=_blank style='color:#2F92EE;'>#基因编辑技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41867, encryptionId=d81a4186e3f, topicName=基因编辑技术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a10c21466636, createdName=marlenexl, createdTime=Thu Dec 19 12:11:00 CST 2019, time=2019-12-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1655567, encodeId=176a165556ed0, content=<a href='/topic/show?id=853555428cc' target=_blank style='color:#2F92EE;'>#抗生素抗性基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55428, encryptionId=853555428cc, topicName=抗生素抗性基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4f5024728688, createdName=lily1624, createdTime=Fri Oct 30 14:11:00 CST 2020, time=2020-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744381, encodeId=77c51e4438180, content=<a href='/topic/show?id=42a7523823' target=_blank style='color:#2F92EE;'>#CRISPR基因编辑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5238, encryptionId=42a7523823, topicName=CRISPR基因编辑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e1c35375117, createdName=guguangxiang, createdTime=Sun Jun 07 18:11:00 CST 2020, time=2020-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666011, encodeId=4de216660110e, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Fri Nov 20 08:11:00 CST 2020, time=2020-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276137, encodeId=ee3612e613757, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Thu Dec 19 12:11:00 CST 2019, time=2019-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630173, encodeId=bfcd16301e33d, content=<a href='/topic/show?id=d81a4186e3f' target=_blank style='color:#2F92EE;'>#基因编辑技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41867, encryptionId=d81a4186e3f, topicName=基因编辑技术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a10c21466636, createdName=marlenexl, createdTime=Thu Dec 19 12:11:00 CST 2019, time=2019-12-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1655567, encodeId=176a165556ed0, content=<a href='/topic/show?id=853555428cc' target=_blank style='color:#2F92EE;'>#抗生素抗性基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55428, encryptionId=853555428cc, topicName=抗生素抗性基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4f5024728688, createdName=lily1624, createdTime=Fri Oct 30 14:11:00 CST 2020, time=2020-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744381, encodeId=77c51e4438180, content=<a href='/topic/show?id=42a7523823' target=_blank style='color:#2F92EE;'>#CRISPR基因编辑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5238, encryptionId=42a7523823, topicName=CRISPR基因编辑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e1c35375117, createdName=guguangxiang, createdTime=Sun Jun 07 18:11:00 CST 2020, time=2020-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666011, encodeId=4de216660110e, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Fri Nov 20 08:11:00 CST 2020, time=2020-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276137, encodeId=ee3612e613757, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Thu Dec 19 12:11:00 CST 2019, time=2019-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630173, encodeId=bfcd16301e33d, content=<a href='/topic/show?id=d81a4186e3f' target=_blank style='color:#2F92EE;'>#基因编辑技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41867, encryptionId=d81a4186e3f, topicName=基因编辑技术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a10c21466636, createdName=marlenexl, createdTime=Thu Dec 19 12:11:00 CST 2019, time=2019-12-19, status=1, ipAttribution=)]
    2020-11-20 yige2012
  4. [GetPortalCommentsPageByObjectIdResponse(id=1655567, encodeId=176a165556ed0, content=<a href='/topic/show?id=853555428cc' target=_blank style='color:#2F92EE;'>#抗生素抗性基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55428, encryptionId=853555428cc, topicName=抗生素抗性基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4f5024728688, createdName=lily1624, createdTime=Fri Oct 30 14:11:00 CST 2020, time=2020-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744381, encodeId=77c51e4438180, content=<a href='/topic/show?id=42a7523823' target=_blank style='color:#2F92EE;'>#CRISPR基因编辑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5238, encryptionId=42a7523823, topicName=CRISPR基因编辑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e1c35375117, createdName=guguangxiang, createdTime=Sun Jun 07 18:11:00 CST 2020, time=2020-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666011, encodeId=4de216660110e, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Fri Nov 20 08:11:00 CST 2020, time=2020-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276137, encodeId=ee3612e613757, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Thu Dec 19 12:11:00 CST 2019, time=2019-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630173, encodeId=bfcd16301e33d, content=<a href='/topic/show?id=d81a4186e3f' target=_blank style='color:#2F92EE;'>#基因编辑技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41867, encryptionId=d81a4186e3f, topicName=基因编辑技术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a10c21466636, createdName=marlenexl, createdTime=Thu Dec 19 12:11:00 CST 2019, time=2019-12-19, status=1, ipAttribution=)]
    2019-12-19 yuandd
  5. [GetPortalCommentsPageByObjectIdResponse(id=1655567, encodeId=176a165556ed0, content=<a href='/topic/show?id=853555428cc' target=_blank style='color:#2F92EE;'>#抗生素抗性基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55428, encryptionId=853555428cc, topicName=抗生素抗性基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4f5024728688, createdName=lily1624, createdTime=Fri Oct 30 14:11:00 CST 2020, time=2020-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744381, encodeId=77c51e4438180, content=<a href='/topic/show?id=42a7523823' target=_blank style='color:#2F92EE;'>#CRISPR基因编辑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5238, encryptionId=42a7523823, topicName=CRISPR基因编辑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e1c35375117, createdName=guguangxiang, createdTime=Sun Jun 07 18:11:00 CST 2020, time=2020-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666011, encodeId=4de216660110e, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Fri Nov 20 08:11:00 CST 2020, time=2020-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276137, encodeId=ee3612e613757, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Thu Dec 19 12:11:00 CST 2019, time=2019-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630173, encodeId=bfcd16301e33d, content=<a href='/topic/show?id=d81a4186e3f' target=_blank style='color:#2F92EE;'>#基因编辑技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41867, encryptionId=d81a4186e3f, topicName=基因编辑技术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a10c21466636, createdName=marlenexl, createdTime=Thu Dec 19 12:11:00 CST 2019, time=2019-12-19, status=1, ipAttribution=)]

相关资讯

Nat Commun:研究发现CRISPR-Cas9基因编辑系统在灵长类中不会导致明显的脱靶效应

CRISPR-Cas9基因编辑系统已被广泛应用于生物和医学研究,研究人员正在尝试利用这一系统进行人类疾病的基因治疗。然而,CRISPR-Cas9系统在临床前的安全性却缺少全面的评估。之前有研究表明,CRISPR-Cas9系统在小鼠中会造成大量脱靶突变。此外,对细胞系的研究发现,Cas9编辑细胞的基因组目标区域存在大片段结构变异。然而这些研究结果由于实验设计和数据分析方面的问题一直都存有争议。

美国首例!CRISPR基因编辑技术应用于癌症治疗

美国宾夕法尼亚大学肿瘤学教授通过CRISPR基因编辑工具对三名晚期癌症的血细胞进行基因改造。

如何利用CRISPR基因编辑技术改良机体白细胞来有效抵御癌症?

日前在美国,研究人员首次利用基因编辑工具来治疗3名晚期癌症患者,同时1期临床试验结果显现出了很大的希望,截止到目前为止,治疗似乎是安全的,而且有更多的结果有望很快发布。为了开发出了一种安全高效的癌症治疗方法,来自宾夕法尼亚大学等机构的科学家们通过研究开发出了一种先进的免疫疗法,在治疗过程中,研究者将患者自身的免疫细胞从其体内移除,随后对这些免疫细胞进行“训练”来使其能够识别特定的癌细胞,最后再将这

Vertex揭示了在首批接受CRISPR/Cas9基因编辑疗法患者中激动人心的数据

Vertex及其合作伙伴CRISPR Therapeutics公布了其CRISPR/Cas9基因编辑疗法CTX001治疗的前两名患者的初步阳性数据。令人印象深刻的数据表明,这两名患有严重血红蛋白病,分别为依赖输血的β地中海贫血(TDT)和严重的镰状细胞病(SCD)的患者很可能可以通过该疗法被治愈。

Adv Mater:基因“剪刀”可用于诊断疾病

CRISPR / Cas技术不仅可以改变基因:根据弗莱堡大学的一项研究,通过使用所谓的基因剪刀,可以更好地诊断癌症等疾病。

主动撤回论文:CRISPR基因编辑婴儿可能会早逝的研究出现错误

今年6月份,美国加利福尼亚大学伯克利分校的生物学家Rasmus Nielsen及Xinzhu Wei在医学杂志《Nature Medicine》发表的一则论文在科学界引起了轩然大波,这篇论文可说是宣告贺建奎“基因编辑婴儿”实验彻底失败的证据。然而时隔4个月,该论文的作者却主动撤回了这篇论文,撤回的原因是他们用来进行研究的英国生物数据库中的基因分型偏倚。